Director at Adaptive Biotechnologies (ADPT) receives 15,625-share award

Rhea-AI Filing Summary

Adaptive Biotechnologies Corp director Robert Hershberg reported an award of common stock. On March 4, 2026, he acquired 15,625 shares of common stock through a grant with a stated price of $0.00 per share. Following this award, his direct holdings total 62,347 shares of common stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider HERSHBERG ROBERT

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	15,625	$0.00	--

Holdings After Transaction: Common Stock — 62,347 shares (Direct)

Footnotes (1)

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HERSHBERG ROBERT

(Last) (First) (Middle)

C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION

1165 EASTLAKE AVE E

(Street)

SEATTLE WA 98109

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Adaptive Biotechnologies Corp [ ADPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/04/2026		A		15,625	A	$0	62,347	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Robert Hershberg by Kyle Piskel, Attorney-in-Fact	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ADPT director Robert Hershberg report?

Robert Hershberg reported receiving a grant of 15,625 shares of Adaptive Biotechnologies common stock on March 4, 2026. The award carried a stated price of $0.00 per share and increased his direct ownership to 62,347 shares after the transaction.

How many Adaptive Biotechnologies (ADPT) shares were granted in this Form 4?

The Form 4 shows a grant of 15,625 shares of Adaptive Biotechnologies common stock. This grant was reported as a stock award with a transaction price of $0.00 per share and brought the director’s directly held shares up to a total of 62,347.

What is Robert Hershberg’s total ADPT shareholding after this grant?

After the March 4, 2026 grant, Robert Hershberg directly holds 62,347 shares of Adaptive Biotechnologies common stock. This total includes the newly awarded 15,625 shares reported in the Form 4 insider trading report filed for this transaction.

Was the Adaptive Biotechnologies stock grant to the director a purchase?

No, the transaction was reported as a grant or award acquisition, not an open-market purchase. The 15,625 shares of common stock carried a stated transaction price of $0.00 per share, indicating an equity award rather than a cash-funded share purchase.

What does transaction code "A" mean in the ADPT Form 4 filing?

In this Form 4, transaction code “A” is described as a grant, award, or other acquisition of common stock. It indicates the director received 15,625 shares as an equity award, with no cash price per share, increasing his direct holdings to 62,347 shares.